Regeneron stock heads toward October 30 earnings after Q2 growth

Published on 10/05/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock was valued at USD 735.20 on October 2, 2026, before its October 30 results date. Q2 revenue rose 16.7 percent to USD 4.29 billion.

Trading-Floor mit Händlern vor Bildschirmen mit steigenden Biotech-Aktiencharts — Regeneron Pharma US75886F1075 zeigt ein Börsen-Editorial mit belebtem Trading-Floor und steigenden Biotech-Sektor-Charts auf Bildschirmen, Illustration mit AI erstellt.

Regeneron stock (ISIN US75886F1075) stood at USD 735.20 on Nasdaq on October 2, 2026, while the biopharmaceutical company prepared for its next results date. The October 30 report will test whether the Q2 growth profile can continue after revenue rose 16.7 percent year over year.

October 30 sets the next test

Regeneron Pharmaceuticals announced on September 24, 2026, that it will publish third-quarter financial and operating results on October 30, 2026, before the U.S. financial markets open. The company also scheduled a conference call for 8:30 a.m. ET, giving investors a defined checkpoint for pipeline progress and commercial performance.

The latest reported quarter was Q2 2026, ended June 30. According to MarketBeat on October 1, 2026, adjusted EPS reached USD 14.29 against USD 10.16 consensus, while revenue was USD 4.29 billion against USD 3.82 billion expected. The EPS beat was USD 4.13, and the revenue increase supplied the clearest operating comparison ahead of Q3.

Sanofi deal adds pipeline value

Regeneron's most recent company event was an expanded Sanofi alliance announced on October 1, 2026. The agreement covers four next-generation antibody medicines, with Sanofi paying USD 1.0 billion upfront and offering up to USD 7.0 billion in milestone payments, according to The Business Standard in a report dated October 2, 2026.

The financial effect is staged rather than immediate because the additional payments depend on development milestones. Regeneron will lead research, while the companies will share development costs and future profits equally, making clinical execution the key variable for the alliance's value.

Consensus stays above the close

MarketBeat listed a Moderate Buy consensus from 26 analysts on October 2, 2026. The average target was USD 809.50, with a high of USD 1,030.00 and a low of USD 185.00, while the average stood USD 74.30 above the USD 735.20 Nasdaq close.

That gap equals 10.11 percent above the reference price, but the spread between USD 185.00 and USD 1,030.00 also shows how widely analyst assumptions differ. For investors, the October 30 report must connect Q2's USD 4.29 billion revenue base with the alliance and pipeline milestones.

Regeneron stock holds a broad range

Regeneron stock was last at USD 735.20 on Nasdaq on October 2, 2026, with a 52-week range of USD 541.00 to USD 859.34 and a market capitalization of USD 75.7 billion.